Bristol-Myers closes on Inhibitex purchase
TRENTON, N.J. (AP) — Bristol-Myers Squibb Co. completed its $2.5 billion acquisition of Inhibitex Inc., a drug developer that Bristol sought as part of its strategy to become a player in the hot market for hepatitis C drugs.
Earlier Monday, Bristol-Myers announced it had finished its tender offer for Inhibitex stock, acquiring about 91 percent of the outstanding shares through midnight Friday for $26 apiece. The...
You have selected to view an article that is older than 60 days. There are several ways to unlock access to NewsOK historical content.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
Please sign in. (You might already have access)
If you are a print subscriber to The Oklahoman, activate your Digital Pass for free access.
Purchase any of The Oklahoman's digital products (digital replica, archives, iPad and smartphone apps), and access to historical NewsOK content is free.
